55 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
to a chronic disease of the tendon. It is a function of an imbalance of tendon breakdown and tendon repair initiated first by an injury which does … not heal properly. This leads to cycles of compromised repair and subsequent re-injury until such time as there is no healing and a degenerative process has
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
of the tendon. It is a function of an imbalance of tendon breakdown and tendon repair initiated first by an injury which does not heal properly … . This leads to cycles of compromised repair and subsequent re-injury until such time as there is no healing and a degenerative process has set in. Typically
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
breakdown and tendon repair initiated first by an injury which does not heal properly. This leads to cycles of compromised repair and subsequent re-injury … a return to normal function. Inadequate rest and improper healing often result in re-injury and rupture.
Current treatments manage pain and facilitate
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
to a chronic disease of the tendon. It is a function of an imbalance of tendon breakdown and tendon repair initiated first by an injury which does not heal … properly. This leads to cycles of compromised repair and subsequent re-injury until such time as there is no healing and a degenerative process has set
20-F/A
p0tny4s2 udbebk
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
v04vr0bovaz
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.4
615ndx6u
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.2
yyo1 5m2pdisoqc1h
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
ztb2x2uwb6re mis1b67
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.2
4ri91imin11aq
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm
20-F/A
vqztxoee
31 Mar 21
Annual report (foreign) (amended)
12:00am
6-K
EX-99.5
9xnlo1gvw k0y1z0q
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.3
ha4u1gp
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.3
2ybvu k43cr
22 Dec 20
Current report (foreign)
3:05pm
6-K
EX-99.2
k3623erifvxvn7wmv
30 Nov 20
Condensed Consolidated Interim Financial Statements
5:19pm